ScionxBio collaborates to develop long-acting xRNA therapeutics
ScionxBio, a preclinical-stage biotechnology company developing next-generation mRNA therapeutics, has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialise extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio’s platform. The agreement brings together the global expertise of Sanofi’s mRNA… Read More